Predict your next investment

Asset/Investment Management
paramountbio.com

See what CB Insights has to offer

Investments

26

Portfolio Exits

12

About Paramount BioCapital Asset Management

Paramount BioCapital is a pharmaceutical development and healthcare investment firm.

Paramount BioCapital Asset Management Headquarter Location

787 Seventh Avenue 48th Floor

New York, New York, 10019,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Paramount BioCapital Asset Management Investments

26 Investments

Paramount BioCapital Asset Management has made 26 investments. Their latest investment was in Tracon Pharmaceuticals as part of their Series A on April 4, 2011.

CBI Logo

Paramount BioCapital Asset Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/6/2011

Series A

Tracon Pharmaceuticals

$14M

Yes

Arcus Ventures, Brookline Investments, JAFCO, Nextech Venture, and Undisclosed Venture Investors

2

2/11/2011

PIPE

Cascadian Therapeutics

$0.15M

Yes

7/19/2007

PIPE - IV

Antares Pharma

$16M

No

6/14/2007

Unattributed VC - III

Subscribe to see more

$99M

Subscribe to see more

0

5/23/2007

Unattributed VC - III

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/6/2011

2/11/2011

7/19/2007

6/14/2007

5/23/2007

Round

Series A

PIPE

PIPE - IV

Unattributed VC - III

Unattributed VC - III

Company

Tracon Pharmaceuticals

Cascadian Therapeutics

Antares Pharma

Subscribe to see more

Subscribe to see more

Amount

$14M

$0.15M

$16M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Arcus Ventures, Brookline Investments, JAFCO, Nextech Venture, and Undisclosed Venture Investors

Sources

2

0

0

Paramount BioCapital Asset Management Portfolio Exits

12 Portfolio Exits

Paramount BioCapital Asset Management has 12 portfolio exits. Their latest portfolio exit was Antares Pharma on April 13, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/13/2022

Acq - Pending

$99M

4

3/9/2018

Acq - P2P

$99M

4

6/24/2017

Acq - P2P

$99M

2

1/30/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/15/2009

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/13/2022

3/9/2018

6/24/2017

1/30/2015

9/15/2009

Exit

Acq - Pending

Acq - P2P

Acq - P2P

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

4

2

10

0

Paramount BioCapital Asset Management Acquisitions

1 Acquisition

Paramount BioCapital Asset Management acquired 1 company. Their latest acquisition was Enhance Biotech on May 24, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/24/2006

$99M

Acquired

Date

5/24/2006

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

Paramount BioCapital Asset Management Team

3 Team Members

Paramount BioCapital Asset Management has 3 team members, including current Managing Director, Asher Nathan.

Name

Work History

Title

Status

Asher Nathan

Managing Director

Current

Scott A. Katzmann

OpusPoint Partners, Opus, First Boston, and Credit Suisse

Senior Managing Director

Former

Nickolay Kukekov

Managing Director

Former

Name

Asher Nathan

Scott A. Katzmann

Nickolay Kukekov

Work History

OpusPoint Partners, Opus, First Boston, and Credit Suisse

Title

Managing Director

Senior Managing Director

Managing Director

Status

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.